Evidence map›Paper›PMID 23566357›Full record

ArticleJournal of neurodevelopmental disorders2013

A pilot open-label trial of minocycline in patients with autism and regressive features.

Carlos A Pardo, Ashura Buckley, Audrey Thurm, Li-Ching Lee, Arun Azhagiri, David M Neville, Susan E Swedo

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurodevelopmental disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00409747 (Treatment of Childhood Regressive Autism With Minocycline), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00409747 phase4completednot on this map

Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS

TypeinterventionalSponsorNational Institute of Mental Health (NIMH)Ran2006 to 2011Enrolled11ConditionsAutism, Minocycline, Regressive AutismArmsMinocycline
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Loss of CC2D1A in Glutamatergic Neurons Results in Autistic-Like Features in Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Review
  20. Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Carlos A PardoDepartment of Neurology, Pathology 627, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Ashura BuckleyPediatrics & Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive, Bldg 10/RM 1C250/MSC 1255, Bethesda, MD, 20892, USA.
Audrey ThurmPediatrics & Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive, Bldg 10/RM 1C250/MSC 1255, Bethesda, MD, 20892, USA.
Li-Ching LeeDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Room E6032, Baltimore, MD, 21205, USA.
Arun AzhagiriDepartment of Neurology, Pathology 627, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
David M NevillePediatrics & Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive, Bldg 10/RM 1C250/MSC 1255, Bethesda, MD, 20892, USA.
Susan E SwedoPediatrics & Developmental Neuroscience Branch, National Institute of Mental Health, 10 Center Drive, Bldg 10/RM 1C250/MSC 1255, Bethesda, MD, 20892, USA.
National Institute of Mental Health · USJohns Hopkins University · USJohns Hopkins Medicine · USNational Institutes of Health · US

Funding

Neuroimmunologic Investigations of Autism Spectrum Disorders (ASD)ZIAMH002915 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI SWEDO, SUSAN · 2009 to 2014
$1.4M
6 · The paper itself

Abstract

backgroundMinocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression.

methodsEleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation.

resultsClinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and α-2 macroglobulin (α-2 M), was also significantly lower (P = 0.028) while the mature BDNF/α-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-α, CD40L, IL-6, IFN-γ and IL-1β when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline.

conclusionsChanges in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration.

trial registrationNCT00409747.

Indexed as

AutismBDNFChemokinesClinical trialCytokinesMetalloproteinasesMicrogliaMinocyclineNeuroinflammationNeurotrophins

Identifiers

PMID23566357
PMCPMC3663771
OpenAlexW2134333739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.